Brief reportAntipsychotic drugs block phencyclidine receptor-mediated neurotoxicity☆
References (11)
- et al.
Novel antipsychotic drugs share high affinity for sigma receptors
Eur J Pharmacol
(1988) Excitatory amino acids and neuropsychiatric disorders
Biol Psychiatry
(1989)General pharmacology of clozapine
Br J Psychiatry
(1992)Subjective effects of narcotic antagonists cyclazocine and nalorphine on the addiction research center inventory (ARCI)
Psychopharmacologia
(1970)- et al.
Non-competitive antagonists of excitatory amino acid receptors
Trends Neurosci
(1987)
Cited by (96)
Early brain development disruption from NMDA receptor hypofunction: Relevance to schizophrenia
2007, Brain Research ReviewsAntioxidants attenuate MK-801-induced cortical neurotoxicity in the rat
2007, NeuroToxicologyEvidence for Neuroprotective Effects of Antipsychotic Drugs: Implications for the Pathophysiology and Treatment of Schizophrenia
2007, International Review of NeurobiologyCitation Excerpt :For example, the dizocilpine‐induced delayed alteration impairment in rats was prevented by pretreatment with clozapine (Hauber, 1993). Also clozapine protected against NMDA‐antagonist neurotoxicity reaction in rats (Farber et al., 1993; Hashimoto et al., 2000). Although traditional antipsychotics (e.g., loxapine, haloperidol, and thioridazine) showed similar effects, their neuroprotective action was not attributed to the drugs’ binding affinity to dopamine receptors, as sulpiride, an agent that binds to dopamine receptors only, did not significantly reduce MK‐801 neurotoxicity at doses up to 30 mg/kg.
Acute D<inf>2</inf>/D<inf>3</inf> Dopaminergic Agonism but Chronic D<inf>2</inf>/D<inf>3</inf> Antagonism Prevents NMDA Antagonist Neurotoxicity
2006, Biological PsychiatryCitation Excerpt :This loss of protection with chronic dosing of a D2/D3 agonist suggested the possibility that chronic administration of a D2/D3 antagonist, through some mechanism (e.g., receptor upregulation), might have the opposite effect and be protective. To test this possibility haloperidol, a D2/D3 antagonist, was given daily for 0 (i.e., one acute injection), 1, 3, or 5 weeks at a dopaminergic dose (1 mg/kg, ip), which does not have significant acute protective effects against NRHypo neurotoxicity (Farber et al 1993). Control groups received DMSO daily for the same amount of time.
- ☆
Supported in part by NIH grants DA 05072, DA 06454, AG 05681 and Research Scientist Award MH 38894 (JWO).